NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Compugen Ltd. (CGEN) Stock Analysis

Compugen Ltd. (CGEN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

CGEN

$2.12

−$0.02 (−0.93%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CGEN with… →

CGEN Key Statistics

As of Oct 21, 2026
Trading
Open
$2.15
Previous Close
$2.14
Day's Range
2.11–2.20
52-Week Range
1.43–3.24
Volume
186.97K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.79
Valuation
Market Cap
$187.55M
P/E Ratio
5.21
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.29
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.53
EPS (ttm)Profit attributable to each share over the last twelve months.
0.38
Financials (FY)
Revenue (FY)
$72.76M+161.14%
Net Income (FY)
$35.34M
Profit marginThe share of revenue left as profit after all costs and taxes.
47.56%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
94.72M
1-Year Return
+20.45%
Dividend and dates
Earnings Date
November 9, 2026
Avg Volume
241.30K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, CGEN closed at $2.12, +20.45% over 1 year.

Compugen Ltd. (CGEN) has a market capitalization of $187.55M.

In fiscal 2025, CGEN reported revenue of $72.76M.

CGEN Stock Return by Calendar Year

Compugen Ltd. (CGEN) 10-year return: what $10,000 became

1 year
$10,000 $12,045
+20.45%
5 years
$10,000 $3,237
−67.63%
10 years
$10,000 $3,533
−64.67%

If you had invested $10,000 in Compugen Ltd. (CGEN) 10 years ago, at the close on October 21, 2016, it would have been worth $3,533 at the close on October 21, 2026: −64.67% in total, −9.88% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+38.56%
2025+0.00%
2024−22.73%
2023+175.00%
2022−83.26%
2021−64.49%
2020+103.19%
2019+174.65%
2018−13.20%
2017−50.98%
2016 (partial year)−23.88%

As of October 21, 2026.

CGEN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$72.76M$35.34M48.6%
2024$27.86M−$14.23M−51.1%
2023$33.46M−$18.75M−56.1%
2022$7.50M−$33.69M−449.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$72.76M$63.51M$31.33M$35.34M48.6%
2024$27.86M$19.93M−$14.89M−$14.23M−51.1%
2023$33.46M$31.46M−$12.99M−$18.75M−56.1%
2022$7.50M$6.53M−$35.37M−$33.69M−449.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CGEN Valuation vs Biotechnology Median

Median of 608 stocks
MetricCGENBiotechnology medianvs median
P/E5.2116.600.3x the median
P/S ratio2.5313.300.2x the median
Profit margin47.56%−38.31%85.9 pts above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 10 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Compugen Ltd. (CGEN) carries a market capitalisation of $187.55M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 75.

CGEN last closed at $2.12 on October 21, 2026. That is −$0.02 (−0.93%) against the previous close. The 52-week range on file runs from $1.43 to $3.24. The latest close sits 48.25% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $72.76M. Against the prior fiscal year total of $27.86M, that is a change of +161.14%. Net income for the same year was $35.34M. The reported profit margin is 47.56%. That is 85.9 percentage points above the Biotechnology median of −38.31%. Trailing earnings per share are 0.38.

Across the 4 fiscal years on file, revenue moves from $7.50M in 2022 to $72.76M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 5.21 times earnings. That is 0.3 times the Biotechnology median of 16.6. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.29. Measured against sales, the shares trade at 2.53 times revenue. On price-to-sales that is 0.2 times the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

Over the trailing twelve months the total return is +20.45%. Measured over 10 years, that is −9.88% a year compounded. Beta against the wider market is reported at 2.79. Annualized volatility over the trailing 10 years is 91.07%.

Growth & Income

The record shows no dividend for CGEN.

The strongest complete calendar year on file is 2023 at +175.00%; the weakest is 2022 at −83.26%. Of the 9 complete calendar years on file, 3 finished higher. So far in 2026 the total return is +38.56%.

Peer Comparison

Compugen Ltd. (CGEN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Compugen Ltd. CGEN $187.55M 5.2
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Compugen Ltd. trades at a P/E of 5.2.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Compugen Ltd.

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti- PD-1/TIGIT bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer. Its preclinical therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and Gilead Sciences, Inc. for the research, development, manufacturing, and commercialization of COM503 and other products. The company was incorporated in 1993 and is headquartered in Holon, Israel.

Visit website →